

## Experienced Genotype 1 With Cirrhosis

**TABLE 175: EXPERIENCED GENOTYPE 1 WITH CIRRHOSIS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12	PR48	4.51 (2.53 to 7.08)	58.42 (26.83 to 76.71)
SOF24 + LDV24		4.70 (1.63 to 7.45)	62.73 (10.44 to 81.67)
SOF12 + LDV12 + RBV12		4.83 (3.09 to 7.29)	63.58 (37.93 to 77.53)
SOF24 + LDV24 + RBV24		5.47 (3.44 to 8.07)	75.05 (44.14 to 84.77)
T12 PR48 q8		3.05 (1.37 to 5.60)	33.89 (6.18 to 63.84)
SIM12 PR24-48 RGT		3.59 (1.52 to 6.04)	42.77 (8.85 to 69.96)
SIM12 PR48		2.72 (0.85 to 5.46)	28.37 (-2.56 to 64.11)
B32 PR36-48 RGT		2.61 (0.69 to 6.00)	26.48 (-5.70 to 66.75)
DCV24 + ASU24		5.28 (3.32 to 7.98)	71.42 (43.13 to 83.06)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24 + PR24		5.51 (3.83 to 8.02)	74.74 (54.38 to 83.55)
SIM12 + SOF12		4.84 (1.91 to 7.64)	64.87 (15.51 to 83.65)
SOF12 + SIM12 + RBV12		4.66 (1.73 to 7.28)	61.72 (12.12 to 82.17)
SOF12 + PR12		2.98 (0.34 to 6.67)	32.67 (-10.89 to 79.19)
PAR/RIT12 + OMB12 + DAS12 + RBV12		5.49 (3.86 to 7.99)	74.22 (55.45 to 83.30)
SOF24 + LDV24	SOF12 + LDV12	1.04 (0.38 to 1.75)	3.43 (-47.02 to 36.64)
SOF12 + LDV12 + RBV12		1.06 (0.81 to 1.67)	4.47 (-15.10 to 30.90)
SOF24 + LDV24 + RBV24		1.19 (0.85 to 2.02)	14.51 (-11.84 to 45.66)
T12 PR48 q8		0.69 (0.29 to 1.40)	-23.34 (-58.61 to 19.94)
SIM12 PR24-48 RGT		0.80 (0.34 to 1.53)	-14.70 (-53.65 to 25.77)
SIM12 PR48		0.61 (0.19 to 1.37)	-29.12 (-66.25 to 18.63)
B32 PR36-48 RGT		0.59 (0.16 to 1.30)	-30.61 (-70.19 to 16.25)
DCV24 + ASU24		1.16 (0.81 to 1.93)	11.77 (-15.86 to 42.33)
DCV24 + ASU24 + PR24		1.21 (0.88 to 2.10)	15.66 (-9.96 to 48.09)
SIM12 + SOF12		1.08 (0.42 to 1.92)	5.92 (-47.07 to 43.14)
SOF12 + SIM12 + RBV12		1.04 (0.39 to 1.90)	2.83 (-49.17 to 42.99)
SOF12 + PR12		0.67 (0.08 to 1.57)	-24.14 (-75.15 to 30.83)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.20 (0.88 to 2.09)	15.33 (-10.22 to 47.81)
SOF12 + LDV12 + RBV12	SOF24 + LDV24	1.01 (0.75 to 2.63)	0.49 (-21.51 to 46.01)
SOF24 + LDV24 + RBV24		1.13 (0.77 to 3.26)	10.67 (-19.95 to 63.05)
T12 PR48 q8		0.67 (0.28 to 2.12)	-26.23 (-64.42 to 33.55)
SIM12 PR24-48 RGT		0.77 (0.33 to 2.36)	-18.33 (-59.11 to 39.97)
SIM12 PR48		0.60 (0.18 to 1.94)	-31.03 (-72.48 to 29.68)
B32 PR36-48 RGT		0.57 (0.16 to 1.78)	-33.21 (-73.71 to 25.99)
DCV24 + ASU24		1.10 (0.77 to 3.04)	7.86 (-20.32 to 57.56)
DCV24 + ASU24 + PR24		1.14 (0.85 to 3.32)	11.32 (-14.18 to 63.56)
SIM12 + SOF12		1.02 (0.43 to 3.03)	1.81 (-47.86 to 58.80)
SOF12 + SIM12 + RBV12		0.99 (0.37 to 2.88)	-0.65 (-54.04 to 55.36)
SOF12 + PR12		0.65 (0.08 to 2.32)	-25.99 (-79.48 to 43.95)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.14 (0.84 to 3.35)	11.14 (-14.73 to 63.36)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.13 (0.79 to 1.61)	10.50 (-17.15 to 35.34)
T12 PR48 q8		0.64 (0.28 to 1.19)	-28.95 (-61.37 to 11.94)
SIM12 PR24-48 RGT		0.75 (0.32 to 1.27)	-20.02 (-56.52 to 16.77)
SIM12 PR48		0.57 (0.18 to 1.18)	-34.30 (-69.24 to 11.28)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
B32 PR36-48 RGT		0.55 (0.15 to 1.07)	-35.52 (-70.76 to 5.13)
DCV24 + ASU24		1.09 (0.81 to 1.44)	7.23 (-15.08 to 26.60)
DCV24 + ASU24 + PR24		1.13 (0.86 to 1.66)	10.58 (-11.75 to 36.76)
SIM12 + SOF12		1.02 (0.40 to 1.55)	1.60 (-49.23 to 32.08)
SOF12 + SIM12 + RBV12		0.98 (0.36 to 1.57)	-1.72 (-53.01 to 33.30)
SOF12 + PR12		0.62 (0.07 to 1.33)	-29.83 (-77.29 to 22.41)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.13 (0.86 to 1.65)	10.23 (-11.99 to 36.62)
T12 PR48 q8	SOF24 + LDV24 + RBV24	0.57 (0.25 to 1.01)	-38.86 (-69.77 to 0.70)
SIM12 PR24-48 RGT		0.66 (0.29 to 1.11)	-30.66 (-66.42 to 7.25)
SIM12 PR48		0.50 (0.16 to 0.99)	-44.60 (-78.05 to -0.86)
B32 PR36-48 RGT		0.48 (0.13 to 1.03)	-46.37 (-81.13 to 2.13)
DCV24 + ASU24		0.97 (0.67 to 1.41)	-3.20 (-30.62 to 25.93)
DCV24 + ASU24 + PR24		1.00 (0.78 to 1.49)	-0.30 (-20.85 to 30.37)
SIM12 + SOF12		0.91 (0.35 to 1.39)	-8.13 (-61.05 to 25.12)
SOF12 + SIM12 + RBV12		0.87 (0.32 to 1.36)	-11.98 (-61.02 to 23.72)
SOF12 + PR12		0.56 (0.06 to 1.19)	-39.03 (-87.46 to 13.78)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.79 to 1.49)	-0.93 (-20.04 to 30.14)
SIM12 PR24-48 RGT	T12 PR48 q8	1.17 (0.45 to 2.91)	8.46 (-36.41 to 49.40)
SIM12 PR48		0.90 (0.44 to 1.40)	-5.21 (-26.30 to 16.21)
B32 PR36-48 RGT		0.85 (0.22 to 2.55)	-7.58 (-53.66 to 44.03)
DCV24 + ASU24		1.71 (0.94 to 3.92)	36.17 (-4.32 to 68.39)
DCV24 + ASU24 + PR24		1.79 (1.07 to 4.03)	40.02 (5.08 to 69.14)
SIM12 + SOF12		1.55 (0.58 to 3.61)	28.81 (-27.14 to 65.14)
SOF12 + SIM12 + RBV12		1.48 (0.54 to 3.53)	25.26 (-26.70 to 64.14)
SOF12 + PR12		0.98 (0.11 to 2.80)	-1.17 (-57.82 to 54.95)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.78 (1.06 to 4.02)	39.53 (4.61 to 68.69)
SIM12 PR48	SIM12 PR24-48 RGT	0.77 (0.22 to 2.15)	-13.61 (-57.72 to 36.60)
B32 PR36-48 RGT		0.74 (0.19 to 2.17)	-15.32 (-61.42 to 38.15)
DCV24 + ASU24		1.46 (0.87 to 3.38)	27.49 (-10.39 to 63.84)
DCV24 + ASU24 + PR24		1.53 (0.98 to 3.47)	31.30 (-1.36 to 65.41)
SIM12 + SOF12		1.34 (0.50 to 3.10)	20.80 (-35.64 to 59.95)
SOF12 + SIM12 + RBV12		1.28 (0.45 to 3.06)	17.06 (-37.79 to 59.95)
SOF12 + PR12		0.85 (0.09 to 2.40)	-8.81 (-65.52 to 48.03)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.52 (0.99 to 3.47)	30.78 (-0.87 to 65.30)
B32 PR36-48 RGT	SIM12 PR48	0.95 (0.24 to 3.79)	-1.98 (-52.32 to 50.45)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
DCV24 + ASU24		1.92 (0.95 to 6.31)	41.29 (-3.41 to 76.46)
DCV24 + ASU24 + PR24		2.02 (1.08 to 6.43)	45.63 (5.95 to 77.55)
SIM12 + SOF12		1.74 (0.60 to 5.71)	33.84 (-24.93 to 73.74)
SOF12 + SIM12 + RBV12		1.65 (0.59 to 5.48)	30.19 (-24.49 to 72.14)
SOF12 + PR12		1.08 (0.12 to 4.18)	3.77 (-56.75 to 63.60)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.01 (1.06 to 6.41)	45.16 (4.42 to 77.23)
DCV24 + ASU24	B32 PR36-48 RGT	1.98 (1.09 to 6.80)	42.35 (6.54 to 74.94)
DCV24 + ASU24 + PR24		2.09 (1.04 to 7.55)	47.18 (3.53 to 80.38)
SIM12 + SOF12		1.83 (0.62 to 6.50)	36.32 (-26.25 to 77.03)
SOF12 + SIM12 + RBV12		1.75 (0.53 to 6.77)	32.72 (-28.87 to 76.43)
SOF12 + PR12		1.17 (0.11 to 4.98)	7.01 (-59.26 to 66.88)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.08 (1.05 to 7.37)	46.80 (3.92 to 79.11)
DCV24 + ASU24 + PR24	DCV24 + ASU24	1.04 (0.80 to 1.50)	3.19 (-18.37 to 31.06)
SIM12 + SOF12		0.94 (0.38 to 1.40)	-5.61 (-55.35 to 25.84)
SOF12 + SIM12 + RBV12		0.90 (0.33 to 1.40)	-9.12 (-59.09 to 25.85)
SOF12 + PR12		0.57 (0.06 to 1.20)	-36.42 (-85.10 to 14.19)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.03 (0.81 to 1.49)	2.66 (-17.17 to 30.01)
SIM12 + SOF12	DCV24 + ASU24 + PR24	0.90 (0.36 to 1.21)	-9.01 (-58.59 to 16.18)
SOF12 + SIM12 + RBV12		0.87 (0.31 to 1.19)	-12.19 (-62.09 to 14.33)
SOF12 + PR12		0.55 (0.06 to 1.09)	-40.53 (-86.71 to 7.70)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.79 to 1.28)	-0.57 (-19.31 to 20.39)
SOF12 + SIM12 + RBV12	SIM12 + SOF12	0.96 (0.39 to 2.28)	-3.00 (-51.73 to 46.78)
SOF12 + PR12		0.63 (0.11 to 1.05)	-25.91 (-64.46 to 3.51)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.11 (0.83 to 2.78)	8.64 (-15.79 to 58.01)
SOF12 + PR12	SOF12 + SIM12 + RBV12	0.67 (0.08 to 1.93)	-23.76 (-79.56 to 37.79)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.15 (0.84 to 3.11)	11.87 (-14.88 to 61.44)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF12 + PR12	1.81 (0.91 to 16.03)	40.01 (-7.81 to 86.25)
Random effect model	Residual deviance	31.23 vs. 33 data points	
	Deviance information criteria	156.914	
Fixed effect model	Residual deviance	31.27 vs. 33 data points	

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
	Deviance information criteria	156.232	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.